Samuel Bates Martin - Dec 23, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Stock symbol
CLDX
Transactions as of
Dec 23, 2021
Transactions value $
-$359,271
Form type
4
Date filed
12/28/2021, 03:02 PM
Previous filing
Nov 17, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $29.3K +3.25K +12.09% $9.02 30.1K Dec 23, 2021 Direct
transaction CLDX Common Stock Options Exercise $10.4K +3.75K +12.45% $2.78* 33.9K Dec 23, 2021 Direct
transaction CLDX Common Stock Sale -$399K -9.5K -28.04% $42.00 24.4K Dec 23, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3.25K -25.43% $0.00 9.53K Dec 23, 2021 Common Stock 3.25K $9.02 Direct F2
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3.75K -13.31% $0.00 24.4K Dec 23, 2021 Common Stock 3.75K $2.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.
F2 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.